Residential College | false |
Status | 已發表Published |
Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease | |
Rostam M.A.1; Piva T.J.1; Rezaei H.B.1; Kamato D.1; Little P.J.1; Zheng W.2; Osman N.1 | |
2015 | |
Source Publication | Clinical and Experimental Pharmacology and Physiology |
ISSN | 14401681 03051870 |
Volume | 42Issue:2Pages:117-124 |
Abstract | Peptidyl-prolyl cis/trans isomerases (PPIases) are a conserved group of enzymes that catalyse the conversion between cis and trans conformations of proline imidic peptide bonds. These enzymes play critical roles in regulatory mechanisms of cellular function and pathophysiology of disease. There are three different classes of PPIases and increasing interest in the development of specific PPIase inhibitors. Cyclosporine A, FK506, rapamycin and juglone are known PPIase inhibitors. Herein, we review recent advances in elucidating the role and regulation of the PPIase family in vascular disease. We focus on peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1), an important member of the PPIase family that plays a role in cell cycle progression, gene expression, cell signalling and cell proliferation. In addition, Pin1 may be involved in atherosclerosis. The unique role of Pin1 as a molecular switch that impacts on multiple downstream pathways necessitates the evaluation of a highly specific Pin1 inhibitor to aid in potential therapeutic drug discovery. |
Keyword | Atherosclerosis Cardiovascular Disease Peptidyl-prolyl Isomerase Pin1 |
DOI | 10.1111/1440-1681.12335 |
URL | View the original |
Language | 英語English |
WOS ID | WOS:000347814900001 |
Scopus ID | 2-s2.0-84920928675 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Faculty of Health Sciences DEPARTMENT OF PHARMACEUTICAL SCIENCES |
Corresponding Author | Osman N. |
Affiliation | 1.RMIT University 2.Zhongshan Ophthalmic Center 3.Monash University 4.International Islamic University Malaysia 5.Tehran University of Medical Sciences |
Recommended Citation GB/T 7714 | Rostam M.A.,Piva T.J.,Rezaei H.B.,et al. Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease[J]. Clinical and Experimental Pharmacology and Physiology, 2015, 42(2), 117-124. |
APA | Rostam M.A.., Piva T.J.., Rezaei H.B.., Kamato D.., Little P.J.., Zheng W.., & Osman N. (2015). Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease. Clinical and Experimental Pharmacology and Physiology, 42(2), 117-124. |
MLA | Rostam M.A.,et al."Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease".Clinical and Experimental Pharmacology and Physiology 42.2(2015):117-124. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment